Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04635059 · ClinicalTrials.gov registry record · Phase 2
Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04635059: Clinical Trial Phase 2 study, sponsored by Medical College of Wisconsin.
NCT04635059 is a Phase 2 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04635059, a Phase 2 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.
Primary Outcome
PSA progression-free survival is defined as the length of time that a subject will be alive and free from PSA progression per PCWG3 guidelines.
Interventions
- DRUG Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2024-10-27 |
| Phase | Phase 2 |
Why NCT04635059 stopped before completion
NCT04635059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Pacritinib is the first listed.
NCT04635059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04635059 about?
NCT04635059 is a clinical study titled "Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer". This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.
What is the current status of trial NCT04635059?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-06-01. Estimated completion is 2024-10-27.
What interventions are being tested in trial NCT04635059?
The interventions under investigation include: Pacritinib (DRUG).
Who is sponsoring clinical trial NCT04635059?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04635059's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI